ATE429919T1 - Prophylaktische und therapeutische verwendung von hydroxysteroiden - Google Patents

Prophylaktische und therapeutische verwendung von hydroxysteroiden

Info

Publication number
ATE429919T1
ATE429919T1 AT02755176T AT02755176T ATE429919T1 AT E429919 T1 ATE429919 T1 AT E429919T1 AT 02755176 T AT02755176 T AT 02755176T AT 02755176 T AT02755176 T AT 02755176T AT E429919 T1 ATE429919 T1 AT E429919T1
Authority
AT
Austria
Prior art keywords
hydroxysteroids
prophylactic
therapeutic use
hydroxy
steroids
Prior art date
Application number
AT02755176T
Other languages
German (de)
English (en)
Inventor
Ernst Wuelfert
Original Assignee
Hunter Fleming Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunter Fleming Ltd filed Critical Hunter Fleming Ltd
Application granted granted Critical
Publication of ATE429919T1 publication Critical patent/ATE429919T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02755176T 2001-08-14 2002-08-13 Prophylaktische und therapeutische verwendung von hydroxysteroiden ATE429919T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0119810A GB2378898A (en) 2001-08-14 2001-08-14 Prophylactic and therapeutic use of hydroxysteroids
PCT/GB2002/003770 WO2003015791A1 (en) 2001-08-14 2002-08-13 Phophylactic and therapeutic use of hydroxysteroids

Publications (1)

Publication Number Publication Date
ATE429919T1 true ATE429919T1 (de) 2009-05-15

Family

ID=9920376

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02755176T ATE429919T1 (de) 2001-08-14 2002-08-13 Prophylaktische und therapeutische verwendung von hydroxysteroiden

Country Status (19)

Country Link
US (1) US8148355B2 (enExample)
EP (1) EP1416937B1 (enExample)
JP (1) JP4541698B2 (enExample)
KR (1) KR100895281B1 (enExample)
CN (1) CN1700920B (enExample)
AT (1) ATE429919T1 (enExample)
AU (1) AU2002321472B2 (enExample)
CA (1) CA2457050C (enExample)
CY (1) CY1109233T1 (enExample)
DE (1) DE60232154D1 (enExample)
DK (1) DK1416937T3 (enExample)
ES (1) ES2324859T3 (enExample)
GB (1) GB2378898A (enExample)
IL (2) IL160362A0 (enExample)
NO (1) NO334819B1 (enExample)
NZ (1) NZ531100A (enExample)
PT (1) PT1416937E (enExample)
RU (1) RU2329049C2 (enExample)
WO (1) WO2003015791A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070231373A1 (en) * 2004-04-28 2007-10-04 Hunter-Fleming Limited Transdermal Steriod for Formulation
US7910755B2 (en) 2004-09-29 2011-03-22 Harbor Biosciences, Inc. Stem cell expansion and uses
JP2010511028A (ja) * 2006-11-30 2010-04-08 ハンター−フレミング・リミテッド プロスタグランジン／シクロオキシゲナーゼの代謝経路の調節
GB0623971D0 (en) * 2006-11-30 2007-01-10 Hunter Fleming Ltd Modulation of prostaglandin/cyclooxygenase metabolic pathways
EP2653163A1 (en) * 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
CN105078954A (zh) * 2015-08-20 2015-11-25 南京华宽信息咨询中心 一种治疗急性肾衰药物及其应用
CN105168197A (zh) * 2015-08-22 2015-12-23 南京华宽信息咨询中心 一种治疗肾功能不全药物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686438A (en) * 1993-03-09 1997-11-11 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5846963A (en) * 1995-06-07 1998-12-08 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5977095A (en) * 1993-03-09 1999-11-02 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome
US5753640A (en) * 1995-06-07 1998-05-19 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
DE69434149T2 (de) * 1993-03-09 2006-07-20 University Of Utah Research Foundation, Salt Lake City Verwendung von dhea oder dessen derivate zur herstellung eines medikaments zur vorbeugung von progressiver gewebe-nekrose, reperfusionsschädigung, bakterieller translokation und vom atemnotsyndrom bei erwachsenen
IT1282289B1 (it) * 1995-06-23 1998-03-16 Sigma Tau Ind Farmaceuti 17-idrossiimminoalchil e 17-idrossiimminometilalchenil ciclopentaperidrofenantreni attivi sul sistema cardiovascolare,
WO1999011271A1 (en) 1997-08-29 1999-03-11 Dalhousie University Use of polycyclic steroid compounds for the manufacture of a medicament for the treatment of cystic kidney diseases, vascular infarction, uremia and related conditions
WO1999052532A1 (en) * 1998-04-14 1999-10-21 Pharmadigm, Inc. Method for reducing central nervous system impairment
GB0003524D0 (en) * 2000-02-15 2000-04-05 Btg Int Ltd Cytoprotective steroids (II)
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB2363983A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone

Also Published As

Publication number Publication date
RU2004104362A (ru) 2005-05-10
EP1416937B1 (en) 2009-04-29
DK1416937T3 (da) 2009-08-24
GB0119810D0 (en) 2001-10-10
WO2003015791A1 (en) 2003-02-27
JP2005506321A (ja) 2005-03-03
CN1700920B (zh) 2012-05-30
HK1065703A1 (en) 2005-03-04
JP4541698B2 (ja) 2010-09-08
EP1416937A1 (en) 2004-05-12
KR100895281B1 (ko) 2009-04-29
CA2457050C (en) 2010-10-12
IL160362A0 (en) 2004-07-25
IL160362A (en) 2011-10-31
US20040248868A1 (en) 2004-12-09
CN1700920A (zh) 2005-11-23
ES2324859T3 (es) 2009-08-18
CY1109233T1 (el) 2014-07-02
NZ531100A (en) 2006-02-24
NO20041057L (no) 2004-03-12
NO334819B1 (no) 2014-06-10
KR20040041577A (ko) 2004-05-17
RU2329049C2 (ru) 2008-07-20
PT1416937E (pt) 2009-07-24
GB2378898A (en) 2003-02-26
US8148355B2 (en) 2012-04-03
CA2457050A1 (en) 2003-02-27
DE60232154D1 (de) 2009-06-10
AU2002321472B2 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
DE60327622D1 (de) Kombinierte antitachykardie - schrittmacher und hochspannungstherapie zur behandlung von ventrikulären arrhythmien
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
DK0933995T3 (da) Fremgangsmåde til behandling af endotelskader
DE60223262D1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
MX338122B (es) Epitopes terapeuticos y usos de los mismos.
GEP20063805B (en) Alkyne-Arylnaphthyridin-4-one as Phosphodiesterase-4 Inhibitors
CY1108211T1 (el) Προφυλακτικη και θεραπευτικη αγωγη των μολυσματικων, αυτοανοσων και αλλεργικων νοσων με ενωσεις βασης μονοσακχαριτη
GB0223038D0 (en) Therapeutic compounds
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
SE9900961D0 (sv) Novel compounds
CY1109233T1 (el) Προφυλακτικη και θεραπευτικη χρηση υδροξυστεροειδων
WO2004054432A3 (en) Methods and devices for therapeutic treatment cardiac and other pathologies
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
EA200501828A1 (ru) Тканепротекторные цитокины с увеличенным терапевтическим окном для защиты, восстановления и стимулирования реагирующих клеток, тканей и органов
ATE317849T1 (de) 5-hydroxysapogenin derivate mit aktivität gegen demenz
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
CY1107562T1 (el) Χρηση των ν-(2-αρυλ-προπιονυλ)-σουκλφοναμιδιων για τη θepαπεια του τραυματος του νωτιαιου μυελου
TR200302008T4 (tr) Dış retina bozukluklarının tedavisine yönelik bir ilaç üretiminde beta-adrenoseptör antagonistlerin kullanımı.
ATE532883T1 (de) Voc-arme fettungsmittel, ihre verwendung in der herstellung und/oder behandlung von leder und häuten, sowie das ensprechende herstellungs- bzw. behandlungsverfahren
WO2003045428A3 (de) Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung
TR200401036T1 (tr) Yüksek kan basıncının tedavisi için citalopram.
IL162268A0 (en) Tempamine compositions and methods of use

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1416937

Country of ref document: EP